NO992609L - Syndecan forsterkerelement og dets anvendelse til Õ mÕlrette genekspresjon - Google Patents

Syndecan forsterkerelement og dets anvendelse til Õ mÕlrette genekspresjon

Info

Publication number
NO992609L
NO992609L NO992609A NO992609A NO992609L NO 992609 L NO992609 L NO 992609L NO 992609 A NO992609 A NO 992609A NO 992609 A NO992609 A NO 992609A NO 992609 L NO992609 L NO 992609L
Authority
NO
Norway
Prior art keywords
syndecan
gene expression
amplifier element
targeted gene
enhancer element
Prior art date
Application number
NO992609A
Other languages
English (en)
Other versions
NO992609D0 (no
Inventor
Markku Jalkanen
Panu Jaakkola
Tapani Vihinen
Original Assignee
Biotie Therapies Ltd Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25059389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO992609(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biotie Therapies Ltd Oy filed Critical Biotie Therapies Ltd Oy
Publication of NO992609D0 publication Critical patent/NO992609D0/no
Publication of NO992609L publication Critical patent/NO992609L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Det er beskrevet et syndecanforsterkerelement, nye proteiner som aktiverer forsterkerelementet, ikke-humane transgene dyr som omfatter dette forsterkerelementet koblet til et strukturelt gen og anvendelse av dette forsterkerelement for å regulere ekspresjon av syndecan og andre gener er også tilveiebragt. Forsterkerelementet kan også anvendes til å målrette ekspresjon av et gen til sårsteder.
NO992609A 1996-12-02 1999-05-31 Syndecan forsterkerelement og dets anvendelse til Õ mÕlrette genekspresjon NO992609L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/760,534 US6017727A (en) 1994-03-07 1996-12-02 Syndecan enhancer element and syndecan stimulation of cellular differentiation
PCT/FI1997/000748 WO1998024921A1 (en) 1996-12-02 1997-12-02 Syndecan enhancer element and its use for targeting gene expression

Publications (2)

Publication Number Publication Date
NO992609D0 NO992609D0 (no) 1999-05-31
NO992609L true NO992609L (no) 1999-05-31

Family

ID=25059389

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992609A NO992609L (no) 1996-12-02 1999-05-31 Syndecan forsterkerelement og dets anvendelse til Õ mÕlrette genekspresjon

Country Status (10)

Country Link
US (1) US6017727A (no)
EP (1) EP0941354A1 (no)
JP (1) JP2001505429A (no)
KR (1) KR20000057361A (no)
AU (1) AU731765B2 (no)
CA (1) CA2272851A1 (no)
HU (1) HUP0001152A3 (no)
NO (1) NO992609L (no)
NZ (1) NZ335328A (no)
WO (1) WO1998024921A1 (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492344B1 (en) 1993-12-01 2002-12-10 Biotie Therapies Corp. Syndecan enhancer element and syndecan stimulation of cellular differentiation
US6528483B2 (en) 1995-06-07 2003-03-04 André Beaulieu Method of producing concentrated non-buffered solutions of fibronectin
WO2009105624A2 (en) * 2008-02-21 2009-08-27 Massachusetts Institute Of Technology Simultaneous delivery of receptors and/or co-receptors for growth factor stability and activity
WO2021150987A1 (en) * 2020-01-22 2021-07-29 Altius Institute For Biomedical Sciences Novel erythroid specific enhancers and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8806893D0 (en) * 1988-03-23 1988-04-27 Unilever Plc Cosmetic composition
WO1990012033A1 (en) * 1989-03-29 1990-10-18 The Board Of Trustees Of The Leland Stanford Junior University Construction and use of synthetic constructs encoding syndecan
JPH04224522A (ja) * 1990-04-27 1992-08-13 Merck & Co Inc 繊維芽細胞増殖因子含有組成物による禿頭症の治療又は予防方法
US5147854A (en) * 1990-05-22 1992-09-15 Hoffmann-La Roche Inc. Tgf-b compositions and method
KR0162670B1 (ko) * 1991-01-15 1999-05-01 마르쿠 잘카넨 세포의 악성 전형을 나타내기 위한 조직 및 체액과 같은 생물학적 물질에서의 신데칸 내용물의 검출
WO1993005167A1 (en) * 1991-09-06 1993-03-18 Children's Medical Center Corporation Cell-type specific heparan sulfate proteoglycans and their uses
US5726058A (en) * 1992-12-01 1998-03-10 Jalkanen; Markku Syndecan stimulation of cellular differentiation
ES2154290T3 (es) * 1992-12-01 2001-04-01 Biotie Therapies Corp Estimulacion de la diferenciacion celular por sindecano.

Also Published As

Publication number Publication date
NO992609D0 (no) 1999-05-31
HUP0001152A3 (en) 2001-09-28
CA2272851A1 (en) 1998-06-11
EP0941354A1 (en) 1999-09-15
JP2001505429A (ja) 2001-04-24
NZ335328A (en) 2000-09-29
HUP0001152A2 (en) 2000-07-28
US6017727A (en) 2000-01-25
KR20000057361A (ko) 2000-09-15
AU731765B2 (en) 2001-04-05
WO1998024921A1 (en) 1998-06-11
AU5222598A (en) 1998-06-29

Similar Documents

Publication Publication Date Title
ATE223484T1 (de) In prostata aktiver gewebespezifischer enhancer
WO2002024899A3 (en) Improved system for regulation of transgene expression
US4933918A (en) Apparatus for frightening noxious animals by means of ultrasonic signals
IT8122077A0 (it) 3-isossazolidinoni erbicidi e intermedi costituiti da acidi idrossamici.
YU9103A (sh) Anti-tnf antitela, kompozicije, postupci i primene
DK0809636T3 (da) Substituerede isoxazoler til behandling af inflammation
DE69203429D1 (de) Verbesserungen an Rohrverbindungen von koaxialen Rohren.
DK0610412T3 (da) Diffusor til en hårtørrer
BR0009762A (pt) Catalisador para produção de ácido acético ou ácido acético e acetato de etila, processo para sua produção e processo para produção de ácido acético ou ácido acético e acetato de etila usando-o
NO992609L (no) Syndecan forsterkerelement og dets anvendelse til Õ mÕlrette genekspresjon
ATE360701T1 (de) Putrescin-n-methyltransferasepromotor
DK0600439T3 (da) Fremgangsmåde til opdræt af spæde husdyr og fodersammensætning
DE60030286D1 (de) Kontrolle der genexpression in eukaryotischen zellen
TR199901421T2 (xx) Peroksidaz �ifreleme dizini kullanarak tek �enekli bir bitkiye b�ceklere kar�� diren� sa�layan metodlar.
EP0853122A3 (en) Transgenic animals lacking functional H2-M molecule
DK0900002T3 (da) H2-M-modificerede transgene dyr
ATE286908T1 (de) Gewebespezifische expression des retinoblastoma- proteins
DE59809309D1 (de) Wässrige Bindemittel auf Polybutadien-Basis
NL7803966A (nl) Smoorspoel.
DE69814148D1 (de) Zielspezifische abgabe zum nukleus mittels protein h von streptococcus
DK113891B (da) Øremærke af formstof til kendetegning af svin, ungkvæg og andre husdyr.
DK0910623T3 (da) Trombinreceptormodificerede transgene dyr
ATE323757T1 (de) Im irak-gen modifizierte transgene mäuse
ATE443148T1 (de) Transkriptionale regulator-nukleinsäuren, polypeptide und verfahren ihrer anwendung
DK0977838T3 (da) H2-O modificerede transgene dyr

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application